WO2024036139A3 - Antibodies binding to clec12a - Google Patents

Antibodies binding to clec12a Download PDF

Info

Publication number
WO2024036139A3
WO2024036139A3 PCT/US2023/071829 US2023071829W WO2024036139A3 WO 2024036139 A3 WO2024036139 A3 WO 2024036139A3 US 2023071829 W US2023071829 W US 2023071829W WO 2024036139 A3 WO2024036139 A3 WO 2024036139A3
Authority
WO
WIPO (PCT)
Prior art keywords
clec12a
antibodies binding
antibodies
compositions
expression
Prior art date
Application number
PCT/US2023/071829
Other languages
French (fr)
Other versions
WO2024036139A2 (en
Inventor
Mengyao JIN
Shihao Chen
Original Assignee
Qlsf Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlsf Biotherapeutics, Inc. filed Critical Qlsf Biotherapeutics, Inc.
Publication of WO2024036139A2 publication Critical patent/WO2024036139A2/en
Publication of WO2024036139A3 publication Critical patent/WO2024036139A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anti-CLEC12A antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of CLEC12A.
PCT/US2023/071829 2022-08-09 2023-08-08 Antibodies binding to clec12a WO2024036139A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263396536P 2022-08-09 2022-08-09
US63/396,536 2022-08-09

Publications (2)

Publication Number Publication Date
WO2024036139A2 WO2024036139A2 (en) 2024-02-15
WO2024036139A3 true WO2024036139A3 (en) 2024-03-28

Family

ID=88020852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/071829 WO2024036139A2 (en) 2022-08-09 2023-08-08 Antibodies binding to clec12a

Country Status (1)

Country Link
WO (1) WO2024036139A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016205200A1 (en) * 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
WO2020130829A1 (en) * 2018-12-20 2020-06-25 Merus N.V. Clec12axcd3 bispecific antibodies and methods for the treatment of disease
WO2021022304A2 (en) * 2019-07-30 2021-02-04 Qlsf Biotherapeutics, Inc. MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69731289D1 (en) 1996-03-18 2004-11-25 Univ Texas IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
MXPA05004677A (en) 2002-10-31 2005-11-17 Genentech Inc Methods and compositions for increasing antibody production.
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016205200A1 (en) * 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
WO2020130829A1 (en) * 2018-12-20 2020-06-25 Merus N.V. Clec12axcd3 bispecific antibodies and methods for the treatment of disease
WO2021022304A2 (en) * 2019-07-30 2021-02-04 Qlsf Biotherapeutics, Inc. MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STEINHARDT JAMES ET AL: "Fab-Arm Exchange Combined with Selective Protein A Purification Results in a Platform for Rapid Preparation of Monovalent Bispecific Antibodies Directly from Culture Media", PHARMACEUTICS, vol. 12, no. 1, 18 December 2019 (2019-12-18), pages 3, XP093100743, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022642/pdf/pharmaceutics-12-00003.pdf> DOI: 10.3390/pharmaceutics12010003 *
YIREN XU ET AL: "Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system", MABS, vol. 7, no. 1, 26 November 2014 (2014-11-26), US, pages 231 - 242, XP055372358, ISSN: 1942-0862, DOI: 10.4161/19420862.2015.989013 *

Also Published As

Publication number Publication date
WO2024036139A2 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
JOP20210253A1 (en) Heavy chain antibodies binding to psma
JOP20210323A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
CA3156451A1 (en) Antibodies having specificity for nectin-4 and uses thereof
WO2018237037A3 (en) Anti-bcma heavy chain-only antibodies
WO2018151821A8 (en) Antibodies to alpha-synuclein and uses thereof
MX2021000708A (en) Heavy chain antibodies binding to cd19.
CR20220656A (en) Multi-specific antibodies binding to bcma
ZA202211667B (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
MX2022013453A (en) Multispecific heavy chain antibodies with modified heavy chain constant regions.
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
MX2022002740A (en) Il-2 conjugates and methods of use to treat autoimmune diseases.
WO2020057540A8 (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer
MX2022007613A (en) Heavy chain antibodies binding to cd38.
MX2020012107A (en) Compositions and methods for treating cancer.
MX2022001449A (en) Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same.
MX2023004869A (en) Antibodies against sars-cov-2 and uses thereof.
CR20230474A (en) Anti-cd19 antibodies and car-t structures
AU2020380603A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2023009882A (en) Anti-muc1-c antibodies and car-t structures.
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
CR20230507A (en) Agonistic anti-il-2r antibodies and methods of use
WO2021100029A3 (en) Prodrugs of fulvestrant
CR20230259A (en) Heavy chain antibodies binding to folate receptor alpha
MX2023009874A (en) Anti-psma antibodies and car-t structures.
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23769038

Country of ref document: EP

Kind code of ref document: A2